Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer66

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer18

Views

Views
November 20252
December 20252
January 20261
February 20260
March 20261
April 20267
May 20265
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States10
United Kingdom3
Argentina2
Angola1
China1
Colombia1
 

Top cities views

Views
Arlington1
Buffalo1
City of Westminster1
Córdoba1
Dallas1
Florida1
Los Angeles1
Medellín1
Waxhaw1